Shots:
Minoryx to receive up front & is eligible to receive milestones and development funding of ~$256M along with royalties
Neuraxpharm gets an exclusive right to commercialize leriglitazone (selective PPAR gamma agonist) in the EU and continues to collaborate with Minoryx to advance the development of leriglitazone while Minoryx holds the full rights to leriglitazone in the US and globally (ex- China)
If Leriglitazone is approved in the EU, it will be the first approved treatment for adult male patients with X-ALD. Both companies continue to advance the therapy for additional X-ALD patient populations and other orphan indications
Ref: Neuraxpharm | Image: Neuraxpharm
